Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

about

Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

Item

http://www.wikidata.org/entity/Q55251007

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

@en

Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

@nl

type

Item

label

Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

@en

Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

@nl

prefLabel

Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

@en

Usefulness of initial plasma dabigatran concentration to predict rebound after reversal.

@nl

P1476

Usefulness of initial plasma dabigatran concentration to predict rebound after reversal

@en

P2093

Agnès Lillo-Le-Louet

http://www.w3.org/2001/XMLSchema#string

Juliette Gay

http://www.w3.org/2001/XMLSchema#string

Marine Lemoine

http://www.w3.org/2001/XMLSchema#string

Pascale Gaussem

http://www.w3.org/2001/XMLSchema#string

P2860

The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis

Idarucizumab for Dabigatran Reversal

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.

Reversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice.

Real-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding.

Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.

Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.

Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.

Idarucizumab for Reversal of Dabigatran Prior to Acute Surgery: A Schematic Approach Based on a Case Report.

P304

e226-e229

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2017.183400

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

David M. Smadja

Nicolas Gendron

P577

2018-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29472359

http://www.w3.org/2001/XMLSchema#string

P932

5927968

http://www.w3.org/2001/XMLSchema#string